Peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription factors that belong to the nuclear hormone receptor superfamily, together with receptors for the thyroid hormone, retinoids, steroid hormones and vitamin D [1] . In mammals, the PPAR family consists of three subtypes of proteins encoded by separate genes: PPARa, PPARg, and PPARd. They act as heterodimers with the retinoid X receptor (RXR) and regulate gene transcription by binding to specific response elements (peroxisome proliferator response element, PPRE) in promoters of the target genes [1] [2] [3] .
Activation of PPARa governs the rate of fatty acid uptake, esterification into triglyceride or oxidation [2, 4, 5] . PPARg is involved in adipocyte differentiation and regulation of fat storage [2, 3, 5] as well as in the maintenance of glucose homeostasis and insulin signaling pathway [3, 6] . PPARs also participate in the down-regulation of inflammatory response. Finally, there is a growing body of evidence that PPARg ligands can inhibit the progression of colon or breast cancers in some experimental models, bringing about differentiation or apoptosis of tumor cells [7] [8] [9] .
Major endogenous PPAR ligands are fatty acids and their derivatives, while synthetic PPAR activators include the peroxisome proliferators and non-steroid anti-inflammatory agents. Exogenous PPARg inducers comprise thiazolidinediones (TZD), well known insulin-sensitizing compounds [1] . TZD efficiently reduces hyperinsulinemia, hyperglycemia, and hypertriglyceridemia as well as decreases high blood pressure, and thereby ameliorates diabetic complications [6, 10] . Two TZD agents, rosiglitazone and troglitazone, were approved for the treatment of insulin-resistance in type II diabetes in humans [1] . As diabetes represents a disease with numerous vascular complications, it is essential to scrutinize the eventual involvement of PPARg activation in the generation of growth factors responsible for angiogenesis and maintenance of vasculature.
Angiogenesis involves the proliferation of endothelial cells from pre-existing capillaries, the breakdown and reassembly of the extracellular matrix and the morphogenic process of endothelial tube formation [11, 12] . A fundamental regulator of normal and pathological angiogenesis is vascular endothelial growth factor (VEGF) produced by many types of cells in response to hypoxia, hypoglycemia or some pro-inflammatory cytokines. The demonstration that VEGF generation is higher in the retina and vitreous body of patients with ischemic retinopathies [13] [14] [15] [16] and evidences that VEGF antagonists may inhibit retinal or iris neovascularization in animal models [17] [18] [19] indicates that VEGF is a potent mediator of retinal angiogenesis in diabetes [20] . It has been reported recently that TZD-mediated PPARg activation may antagonize the VEGF activity by downregulation of the expression of VEGF receptors in endothelial cells [21] or by inducing endothelial cell apoptosis [22] . However, the involvement of TZD drugs in the regulation of generation of VEGF protein has not been studied yet.
In this paper, we examined the effect of PPARg activation on the generation of VEGF in vascular smooth muscle cells (VSMC) and macrophages. Our results demonstrate that the generation of VEGF is increased by PPARg ligands.
MATERIALS AND METHODS
Chemicals. PPARg ligands, ciglitazone and 15-deoxyprostaglandin-J 2 (PGJ 2 ), were from Biomol, interleukin-1b (IL-1b) and lipopolysaccharide (LPS) were purchased from Sigma, culture media (DMEM F-12, RPMI-1641) and fetal calf serum (FCS) were from Gibco. Tfx-50 liposomes and lactate dehydrogenase (LDH) release kit were bought from Promega and QIAfilter maxiprep kit from Qiagen. The ELISA kit for mouse VEGF was from R&D and the kit for measurement of luciferase activity was purchased from Roche Diagnostic.
Cell culture. Murine macrophage-like cells RAW264.7 were cultured in RPMI-1641 medium supplemented with 10% FCS. Vascular smooth muscle cells (VSMC) were isolated by collagenase digestion of thoracic rat aorta and cultured in DMEM F-12 medium supplemented with 5% FCS. VSMC of 5th to 10th passages were used for experiments. VSMC or RAW were seeded in 24-well plates and grown to confluency. Before experiments, the cells were starved overnight in a medium containing 0.5% FCS. Then, the medium was replaced with the fresh FCS and cells were supplemented with PPAR activators: ciglitazone (0.3-10 mM) or PGJ 2 (0.1-10 mM). Four hours later, some VSMC and RAW were additionally stimulated with IL-1b (5 ng/ml) or LPS (100 ng/ml), respectively. After 24 h, the culture media were collected and concentrations of VEGF were measured by ELISA, while cell viability was assessed by colorimetric measurement of LDH levels. RT-PCR. After removed of culture medium, total RNA was isolated from the cells by acid guanidinium thiocyanate-phenol-chloroform extraction [23] . RT-PCR reactions were performed on 100 ng of RNA with primers recognizing PPARg (5¢-TCT CTC CGT AAT GGA AGA CC and 5¢-GCA TTA TGA GCA TCC CCA C) or VEGF (5¢-CAC CGC CTC GGC TTG TCA CAT and 5¢-CTG CTG TCT TGG GTG CAT TGG). The amplifications of the housekeeping GAPDH gene were made as an internal control. RT-PCR was carried out for 40 min at 65°C with Tth polymerase (2.5 U/10 ml) in the presence of Mn 2+ (2.5 mM). After the addition of chelating buffer (EGTA 750 mM, Mg 2+ 2.5 mM; total volume of PCR mixture -50 ml), the PCR was performed for 35 cycles at 94°C -40 s, 58°C -40 s, and 72°C -50 s profile. PCR products were analyzed by agarose gel electrophoresis. Transient transfection assay. To confirm the transcriptional activity of PPAR in the studied cells, VSMC and RAW macrophages were transfected with reporter plasmid pGL3 containing three copies of PPAR-responsive element (PPRE) which regulated luciferase gene expression (construct was a kind gift by Dr. Lluis Fajas, France). To check the transcriptional regulation of VEGF promoter activity, we used the human VEGF gene promoter (-2279 to +54) cloned into luciferase reporter plasmid pGL2 (construct was a kind gift by Dr. Hideo Kimura, Japan). Plasmids were amplified in HB101 E. coli and isolated using QIAfilter maxiprep. RAW and VSMC grown to 70-80% confluence were transfected in 24-well plates using 1.5 ml Tfx-50 liposomes and 0.5 mg plasmid DNA per well, according to the vendor's protocol. After 24 h, the medium was refreshed and, where necessary, supplemented with ciglitazone (3 mM), or PGJ 2 (3 mM). The cells were collected 48 h later, lysed and subjected to luciferase assay.
Statistical analysis. All experiments were repeated 3-7 times, in duplicate or triplicate. Data are presented as means ± S.D. Statistical comparison were made by Student's t-test or by ANOVA followed by Tukey test.
RESULTS

Expression and transcriptional activity of PPARg
Expression of PPARg in the studied cells was confirmed by RT-PCR analysis. The presence of PPARg mRNA was detected both in VSMC and in RAW (Fig. 1, insert) . Both in VSMC and RAW cells transfected with reporter plasmid, PPARg ligands significantly increased the PPRE-driven luciferase activity Vol. 47 PPARg ligands increase the generation of VEGF( Fig. 1) . The obtained results imply that PPARg is an active transcription factor both in macrophages and VSMC. Neither ciglitazone (0.3-10 mM) nor PGJ 2 (0.1-10 mM) influenced the viability of VSMC and RAW, as determined by LDH-release test. Increased toxicity was detected only in RAW incubated with the highest dose of PGJ 2 (data not shown).
Effect of PPARg ligands on the generation of VEGF protein
To determine the effect of PPARg ligands on VEGF release from the studied cells, the concentrations of VEGF protein in the culture media were measured by ELISA. After 24 h incubation, both types of cells released comparable amounts of VEGF protein, approximately 100-200 pg/ml. IL-1b significantly increased the generation of VEGF in VSMC, while stimulation of RAW macrophages with LPS did not influence the VEGF synthesis (not shown).
In VSMC, ciglitazone (3-10 mM) and PGJ 2 (0.1-10 mM) significantly increased the generation of VEGF both in resting and IL-1b-stimulated cells (Fig. 2) . A very similar effect of PPARg ligands was also observed in resting or LPS-stimulated RAW macrophages (Fig. 3) . Incubation of RAW with ciglitazone resulted in a potent upregulation of VEGF generation and this influence was even stronger than in VSMC. PGJ 2 also increased VEGF generation in RAW, although only the highest non-toxic concentration (3 mM) was effective.
Effect of PPARg ligands on the expression of VEGF mRNA
The expression of VEGF mRNA in the studied cells was confirmed by RT-PCR analysis. The presence of mRNAs for VEGF 120 and VEGF 164 isoforms was regularly detected in VSMC (Fig. 4a) . In RAW macrophage-like cells, a higher expression of VEGF 120 was usually observed (Fig. 4b) . Both in VSMC and in RAW, the RT-PCR signal was stronger in cells incubated with ciglitazone or PGJ 2 (Fig. 4) .
Effect of PPARg ligands on the activity of VEGF gene promoter
The cells were transfected with reporter plasmid containing the VEGF gene promoter and then incubated with ciglitazone or PGJ 2 . In VSMC, as well as in RAW macrophages, some basal activity of the VEGF promoter was observed, as determined by luciferase assay. In both cell types, the promoter activity was slightly but significantly enhanced by ciglitazone or PGJ 2 (Fig. 5) . These data indicate that the effect of PPARg ligands on VEGF mRNA expression may be, in part, mediated by an increased transcription rate from the VEGF promoter.
DISCUSSION
We showed that PPARg ligands increase the synthesis of VEGF, a major angiogenic factor. We used two, well-characterized PPARg agonists, namely a metabolite of the eicosanoid prostaglandin-J 2 , which is the most potent natural ligand of PPARg [1, 24] , and ciglitazone (a TZD derivative), which is a highly specific exogenous PPARg activator [1, 6] .
Both ligands effectively increased VEGF mRNA expression and protein release. Very recently, a similar finding was reported for human vascular smooth muscle cells [25] . The involvement of PPARg activation in the upregulation of VEGF synthesis was also suggested in human monocyte cell line [26] . Our results fully confirm these reports and extend them, suggesting that the augmentation of VEGF protein synthesis is, in part, dependent on the increased activity of VEGF promoter.
So far, the expression of PPARg was described in adipose tissues, liver, adrenal gland, spleen, skeletal muscles and retina [1] . High expression has also been detected in activated macrophages, including murine RAW Vol. 47 PPARg ligands increase the generation of VEGF 1151 VEGF is produced in numerous ocular cells, including retinal pigment cells, pericytes, endothelial cells and glial cells [42] . Hypoxia-induced up-regulation of the expression of both VEGF and VEGF receptors is the major mediator of retinopathies [20, 43] . Studies in transgenic mice evidenced that increased expression of VEGF in the retina is sufficient for retinal neovascularization, even in normoxic conditions [20] . Therefore, the effect of PPARg activation on VEGF generation might be important in diabetic patients endangered with retinopathy and treated with insulin-sensitizing TZD.
Recently, two papers have reported that the activation of PPARg in endothelial cells strongly inhibits VEGF-induced angiogenesis [21, 22] . High doses of PGJ 2 or TZD inhibited the proliferation of endothelial cells and their differentiation into tube-like structures, dependent on the reduced expression of VEGF-R1 and VEGF-R2 receptors [21] . Our data suggest, however, that the influence of PPARg activation is pleiotropic and that the decrease in VEGF receptor expression in endothelial cells is accompanied by increased VEGF generation in VSMC or macrophages. The final outcome is difficult to predict and may depend on experimental models.
Ligand-activated PPARg protein forms a heterodimer with RXRa and may directly regulate gene expression through PPRE region in the target gene promoter [1, 3, 4] . The VEGF gene promoter, however, does not contain the PPRE motif. Therefore, it seems that PPARg ligands upregulate VEGF expression indirectly. Analysis of the VEGF gene promoter region reveals several potential binding sites for transcription factors activating protein-1 and -2 (AP-1, AP-2), stimulatory protein-1 (SP-1) and hypoxia responsive element-1 (HIF-1) [44] . Therefore, it is surprising that PPARg, which is known to inhibit AP-1 activity [41] , actually upregulates VEGF expression. On the other hand, AP-1 together with HIF-1 are the major factors responsible for hypoxia-induced generation of VEGF [44] . In normoxia, basal and cytokine-enhanced VEGF expression is mediated mostly by SP-1 protein, which interacts with four SP-1 binding sites located in the proximity of transcription start site [45, 46] . There is no data concerning the mutual regulation of PPAR and SP-1. Some observations suggest, however, that these transcription factors may act synergistically and overexpression of PPAR or RXR may enhance the effect of SP-1 in the up-regulation of gene transcription [47] . This might be one of the possible explanations of PPARg-mediated upregulation of basal and cytokine-induced VEGF production.
TZDs, which are commonly accepted as highly specific ligands for PPARg, are also able to activate the RZRa nuclear receptor [48] . RZRa is involved in regulation of cellular differentiation, the inflammatory response, and lipid metabolism [48, 49] . VEGF gene promoter analysis shows the presence of two RZR consensus-like motifs (at -1834 and -167), one of them overlapping with the AP-1 binding site. Therefore, the involvement of RZRa transcription factor in ciglitazone-mediated upregulation of VEGF expression cannot be excluded.
Finally, it has been shown that PPARg ligands upregulate the expression of the heme oxygenase-1 (HO-1) gene [50, 51] . In VSMC and macrophages, HO-1 activation significantly augmented the synthesis of VEGF [52] . Therefore, we can speculate that PPARg-induced HO-1 activity might contribute to the observed upregulation of VEGF production.
In summary, we show that both exogenous and endogenous ligands of PPARg upregulate the generation of VEGF. Probably the increase in the synthesis of mRNA and protein depends in part on the activation of the VEGF promoter. Further examinations are necessary to determine the molecular mechanism underlying this effect.
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